ADIL — ADIAL PHARMACEUTICALS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1513525 ·
Last close
$2.24
Market Cap
$4.80M
52W High
$2.63
52W Low
$1.31
ADV30
177,440
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -2,001,481 | -2,022,392 | 5,227,321 | 4,584,100 | 1,510,071 |
| Dec 2025 | 0 | — | -1,885,379 | -1,996,163 | 6,673,367 | 5,881,217 | 1,396,909 |
| Sep 2025 | 0 | — | -1,764,078 | -1,793,651 | 5,659,847 | 4,606,289 | 1,154,756 |
| Jun 2025 | 0 | — | -1,882,712 | -1,958,556 | 6,801,703 | 5,914,980 | 1,211,027 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-6,492,603
Investing CF
$150,000
Financing CF
$8,473,295
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-24.50
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-89,972,494
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-7,799,462
Pretax Income TTM
$-7,977,171
Interest Exp TTM
—
Analysts
2
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -7,799,462 | -7,977,171 | 6,673,367 | 1,396,909 | — | -6,492,603 |
| Dec 2024 | 0 | -8,284,457 | -13,197,451 | 5,043,942 | 975,858 | — | -6,922,306 |
| Dec 2023 | 0 | -6,887,947 | -5,123,341 | 4,736,605 | 653,076 | — | -6,806,809 |
| Dec 2022 | 0 | -10,859,475 | -12,731,416 | 5,732,804 | 2,456,310 | — | -11,185,985 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.49
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CTTH | CTT PHARMACEUTICAL HOLDINGS, INC. | $4.85M | $0.08 | — |
| PULM | Pulmatrix, Inc. | $4.89M | $1.34 | — |
| MTNB | Matinas BioPharma Holdings, Inc. | $4.66M | $0.73 | — |
| DRMA | Dermata Therapeutics, Inc. | $4.95M | $1.23 | — |
| PMHS | Polomar Health Services, Inc. | $4.56M | $0.15 | — |
News headlines (Yahoo Finance, 1h cache)
Adial Pharmaceuticals Reports 2026 First Quarter Financial Results and Provides Business Update
2026-05-11 12:30 · Yahoo
Adial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market Exclusivity Through 2045
2026-04-29 13:07 · Yahoo
Adial Pharmaceuticals Submits Application to FDA Commissioner’s National Priority Voucher (CNPV) Pilot Program for AD04 Clinical Development Program
2026-04-27 12:47 · Yahoo
Adial Pharmaceuticals Successfully Completes Manufacturing of Demonstration Batch Production, Enabling Clinical and Registration Production for AD04 Planned Phase 3 Trial
2026-04-22 13:35 · Yahoo
Adial Pharmaceuticals Commends Congress on Introduction of Bipartisan Legislation Expanding Access to Emerging AUD Therapies for Veterans
2026-03-24 13:07 · Yahoo
Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update
2026-03-06 13:00 · Yahoo
Adial Pharmaceuticals Signs an Exclusive AD04 Collaboration Framework with Molteni Farmaceutici for Europe which Anticipates Nearly $60 Million in Potential Royalties and Milestones upon execution of
2026-03-03 13:17 · Yahoo
Adial Pharmaceuticals Regains Full Compliance with Nasdaq Listing Requirement
2026-02-24 14:00 · Yahoo
Adial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden from Two Studies to One
2026-02-23 13:30 · Yahoo
Adial Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
2026-02-17 14:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.